Loading…
Pulmatrix, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -90.7% over 5Y.
today you would have $100.63▼ -89.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.23 | $6.98 | $1.86 | $3.88 | $8.76 | $23.80 | $17.20 | $48.00 | $282.00 | $118.00 | $840.00 | $1,750.00 | |
| P/S | 5.3x | — | 3.3x | 0.9x | 2.3x | 5.6x | 5.3x | 2.2x | 125.9x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| JUNSJupiter Neurosciences Inc | $4.18 | — | — | — | -1888.70% | $5.51M |
| PMCBPharmaCyte Biotech, Inc. | $0.52 | — | 0.2x | — | -44.72% | $5.53M |
| NCNANuCana plc | $1.33 | 0.0x | 0.2x | — | -70.26% | $5.54M |
| CVKDCadrenal Therapeutics, Inc. | $1.54 |
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Company description provided by Yahoo Finance.
| 93.8x |
| 12.6x |
| 50.8x |
| 4.7x |
| P/B | 1.6x | 2.1x | 2.8x | 0.4x | 0.5x | 0.6x | 2.9x | 1.6x | 1.6x | 3.1x | 1.2x | 1.9x | — |
| EPS | -$1.41 | -$2.62 | -$3.87 | -$5.46 | -$8.63 | -$13.43 | -$24.60 | -$99.60 | -$186.40 | -$376.00 | -$646.00 | -$6,904.00 |
| Profit margin | -390.23% | — | -122.46% | -193.49% | -310.26% | -390.23% | -152.83% | -260.38% | -13439.87% | -5389.85% | -3334.49% | -2178.77% | -6859.09% |
| ROE | -106.84% | -135.49% | -106.84% | -78.47% | -60.55% | -42.51% | -83.44% | -186.91% | -173.62% | -178.12% | -317.81% | -80.25% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.2x |
| — |
| -275.16% |
| $5.49M |
| CDIOCardio Diagnostics Holdings, Inc. | $1.85 | — | 0.7x | — | -75.44% | $5.48M |
| LABTLakewood-Amedex Biotherapeutics Inc. | $2.30 | — | 1.2x | — | -402.83% | $5.45M |